AnaptysBio, Inc. (NASDAQ:ANAB) Receives $82.00 Average Price Target from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has earned an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $82.00.

A number of brokerages recently weighed in on ANAB. Piper Sandler decreased their price objective on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Weiss Ratings downgraded AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. UBS Group boosted their price target on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. HC Wainwright assumed coverage on AnaptysBio in a research report on Wednesday, June 10th. They set a “buy” rating and a $95.00 target price on the stock. Finally, Leerink Partners set a $90.00 price target on shares of AnaptysBio in a research report on Friday, May 15th.

AnaptysBio Stock Performance

ANAB stock opened at $54.77 on Tuesday. The firm has a 50 day moving average price of $57.46 and a 200-day moving average price of $58.05. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -50.71 and a beta of 0.72. AnaptysBio has a 52-week low of $11.40 and a 52-week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. As a group, sell-side analysts forecast that AnaptysBio will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently bought and sold shares of the stock. Tema ETFs LLC boosted its stake in shares of AnaptysBio by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after purchasing an additional 201 shares during the period. Los Angeles Capital Management LLC grew its stake in AnaptysBio by 1.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock worth $732,000 after acquiring an additional 225 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares during the period. Larson Financial Group LLC raised its holdings in shares of AnaptysBio by 21.2% in the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 284 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC raised its holdings in shares of AnaptysBio by 1.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after purchasing an additional 500 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.